The Biopharma company will collaborate with existing investor Ipsen to develop new botulinum treatments in a deal that could be worth more than $90m to Syntaxin.
UK-based biopharmaceutical company Syntaxin signed a strategic collaboration agreement with France-based biotechnology corporation Ipsen on Thursday to discover and develop new compounds focused on botulinum toxins.
The agreement involves Ipsen paying Syntaxin an undisclosed technology access fee upfront and up to $9m in milestone payments over the first three years of the collaboration. Commercial milestones and royalties for Syntaxin could potentially top $90m.
Ipsen was among Syntaxin’s series C investors when Syntaxin closed its series C round in November…
